Figure 2.
Kaplan-Meier plots for PFS, per investigator assessment, for patients with BRAF V600–mutant LCH receiving dabrafenib monotherapy or dabrafenib plus trametinib. Kaplan-Meier plots showing PFS based on investigator assessment among pediatric patients with BRAF V600–mutant LCH treated with dabrafenib monotherapy (A) or dabrafenib plus trametinib (B).

Kaplan-Meier plots for PFS, per investigator assessment, for patients with BRAF V600–mutant LCH receiving dabrafenib monotherapy or dabrafenib plus trametinib. Kaplan-Meier plots showing PFS based on investigator assessment among pediatric patients with BRAF V600–mutant LCH treated with dabrafenib monotherapy (A) or dabrafenib plus trametinib (B).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal